FR14C0010I2 - Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques - Google Patents
Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaquesInfo
- Publication number
- FR14C0010I2 FR14C0010I2 FR14C0010C FR14C0010C FR14C0010I2 FR 14C0010 I2 FR14C0010 I2 FR 14C0010I2 FR 14C0010 C FR14C0010 C FR 14C0010C FR 14C0010 C FR14C0010 C FR 14C0010C FR 14C0010 I2 FR14C0010 I2 FR 14C0010I2
- Authority
- FR
- France
- Prior art keywords
- enoic
- trifluoromethylphenyl
- cyano
- hydroxy
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28168501P | 2001-04-05 | 2001-04-05 | |
GBGB0123571.2A GB0123571D0 (en) | 2001-04-05 | 2001-10-02 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
PCT/US2002/010773 WO2002080897A1 (fr) | 2001-04-05 | 2002-04-04 | Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques |
Publications (2)
Publication Number | Publication Date |
---|---|
FR14C0010I1 FR14C0010I1 (fr) | 2014-03-14 |
FR14C0010I2 true FR14C0010I2 (fr) | 2014-11-21 |
Family
ID=26246599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR14C0010C Active FR14C0010I2 (fr) | 2001-04-05 | 2014-02-05 | Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP1381356B1 (fr) |
AR (1) | AR033459A1 (fr) |
AT (1) | ATE396719T1 (fr) |
CA (1) | CA2443285C (fr) |
CY (1) | CY2014004I2 (fr) |
DE (1) | DE60226855D1 (fr) |
DK (1) | DK1381356T3 (fr) |
ES (1) | ES2305287T3 (fr) |
FR (1) | FR14C0010I2 (fr) |
LU (1) | LU92366I2 (fr) |
PA (1) | PA8542901A1 (fr) |
PT (1) | PT1381356E (fr) |
SI (1) | SI1381356T1 (fr) |
UY (1) | UY27244A1 (fr) |
WO (1) | WO2002080897A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7323443B2 (en) | 2002-12-12 | 2008-01-29 | Agennix Inc. | Lactoferrin in the reduction of pain |
EP1804782A1 (fr) * | 2004-10-19 | 2007-07-11 | Aventis Pharmaceuticals Inc. | Emploi du (4'-trifluoromethylphenyl)amide de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique dans le traitement d affections abdominales inflammatoires |
CA2589367C (fr) | 2004-12-21 | 2015-02-03 | Laboratoires Serono S.A. | Derives amino cycliques sulfonyle et utilisation de ceux-ci |
RS51957B (en) | 2005-01-31 | 2012-02-29 | Merck Serono Sa. | N-HYDROXIAMIDE DERIVATIVES AND THEIR USE |
WO2007025991A2 (fr) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Traitement de la nevrite optique |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
EP2100881A1 (fr) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Dérivés d'acide pyrimidinyl- ou pyridinylaminobenzoïque |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
EP2135610A1 (fr) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combinaison comportant des inhibiteurs DHODH et de la méthotrexate |
EP2228367A1 (fr) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Sels adjuvants d'amines contenant des groupes hydroxyle et/ou carbonyle avec des dérivés d'acides aminonicotiques en tant qu'inhibiteurs de la DHODH |
EP2230232A1 (fr) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Sels adjuvants de trométhamine dotés de dérivés d'acide azabiphénylaminobenzoïque en tant qu'inhibiteurs de la DHOD |
EP2239256A1 (fr) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sel de sodium de l'acide 5-cyclopropyl-2-{[2-(2,6-difluorophényl)pyrimidin-5-yl]amino}benzoïque en tant qu'inhibiteurs de la DHOD |
EP2277515A1 (fr) * | 2009-07-10 | 2011-01-26 | Sanofi-Aventis | Utilisation d'une combinaison de teriflunomide et d'interféron bêta pour le traitement de la sclérose en plaques |
DK2477611T3 (en) | 2009-09-18 | 2017-07-10 | Sanofi Sa | (Z) -2-CYANO-3-HYDROXYBUT-2-ENIC ACID (4'-TRIFLUORMETHYLPHENYL) AMID TABLE FORMULATIONS WITH IMPROVED STABILITY |
EP2314577A1 (fr) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Procédé de fabrication de l'acide 2-[(3,5-difluoro-3'-méthoxy-1,1'-biphényl-4-yl)amino]nicotinique |
US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
WO2012109329A2 (fr) | 2011-02-08 | 2012-08-16 | Children's Medical Center Corporation | Méthodes de traitement d'un mélanome |
EP2762135A1 (fr) * | 2013-02-04 | 2014-08-06 | Sanofi | Procédés permettant de réduire le risque d'une interaction de la rosuvastatine et du tériflunomide indésirable chez des patients atteints de sclérose en plaques |
WO2016189406A1 (fr) | 2015-05-23 | 2016-12-01 | Ftf Pharma Private Limited | Composition pharmaceutique de tériflunomide |
JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
GR1010137B (el) | 2020-12-15 | 2021-12-07 | Φαρματεν Α.Β.Ε.Ε., | Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES448386A1 (es) | 1975-06-05 | 1978-04-16 | Hoechst Ag | Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico. |
DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
TW314467B (fr) | 1993-03-31 | 1997-09-01 | Hoechst Ag | |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
-
2002
- 2002-04-04 SI SI200230727T patent/SI1381356T1/sl unknown
- 2002-04-04 AT AT02763962T patent/ATE396719T1/de active
- 2002-04-04 ES ES02763962T patent/ES2305287T3/es not_active Expired - Lifetime
- 2002-04-04 DE DE60226855T patent/DE60226855D1/de not_active Expired - Lifetime
- 2002-04-04 PT PT02763962T patent/PT1381356E/pt unknown
- 2002-04-04 DK DK02763962T patent/DK1381356T3/da active
- 2002-04-04 WO PCT/US2002/010773 patent/WO2002080897A1/fr not_active Application Discontinuation
- 2002-04-04 EP EP02763962A patent/EP1381356B1/fr not_active Expired - Lifetime
- 2002-04-04 AR ARP020101245A patent/AR033459A1/es not_active Application Discontinuation
- 2002-04-04 CA CA002443285A patent/CA2443285C/fr not_active Expired - Fee Related
- 2002-04-04 EP EP08004647A patent/EP1935416A3/fr not_active Ceased
- 2002-04-05 PA PA20028542901A patent/PA8542901A1/es unknown
- 2002-04-05 UY UY27244A patent/UY27244A1/es unknown
-
2014
- 2014-01-23 CY CY2014004C patent/CY2014004I2/el unknown
- 2014-01-29 LU LU92366C patent/LU92366I2/fr unknown
- 2014-02-05 FR FR14C0010C patent/FR14C0010I2/fr active Active
Also Published As
Publication number | Publication date |
---|---|
EP1935416A3 (fr) | 2008-10-22 |
CY2014004I1 (el) | 2015-12-09 |
PT1381356E (pt) | 2008-07-24 |
PA8542901A1 (es) | 2003-11-12 |
AR033459A1 (es) | 2003-12-17 |
DK1381356T3 (da) | 2008-09-22 |
ES2305287T3 (es) | 2008-11-01 |
EP1935416A2 (fr) | 2008-06-25 |
EP1381356A1 (fr) | 2004-01-21 |
CY2014004I2 (el) | 2015-12-09 |
CA2443285A1 (fr) | 2002-10-17 |
WO2002080897A1 (fr) | 2002-10-17 |
FR14C0010I1 (fr) | 2014-03-14 |
UY27244A1 (es) | 2002-07-31 |
LU92366I2 (fr) | 2014-03-31 |
EP1381356B1 (fr) | 2008-05-28 |
SI1381356T1 (sl) | 2008-12-31 |
ATE396719T1 (de) | 2008-06-15 |
DE60226855D1 (de) | 2008-07-10 |
CA2443285C (fr) | 2007-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR14C0010I2 (fr) | Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques | |
FR2843295B1 (fr) | Instrument pour le traitement de fracture de tassement de corps vertebraux | |
FR2854074B1 (fr) | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques | |
FR2846870B1 (fr) | Materiel d'osteosynthese pour le traitement d'un cubitus"long" | |
ITMI20022234A1 (it) | Apparecchiatura e procedimento per l'esecuzione di codifica | |
FR13C0044I2 (fr) | Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine | |
MA26950A1 (fr) | Nouveaux retinoides pour le traitement de l'emphyseme | |
FR2829142B1 (fr) | Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues | |
ITMI20012052A0 (it) | Procedimento per la capitazione e l'abbattimento delle polveri volatili | |
GB0123571D0 (en) | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis | |
MA26289A1 (fr) | Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales | |
MA24332A1 (fr) | Utilisation de 1-hydroxy-2- pyridones pour le traitement d'infections de la peau | |
PL363837A1 (en) | Purification of 2-nitro-4-methylsulphonylbenzoic acid | |
FR2800614B1 (fr) | Composition pour le traitement des infections des voies respiratoires | |
FR2835851B1 (fr) | Composition pour le traitement d'alliages de magnesium | |
MA26117A1 (fr) | Nouveau compose pour le traitement de l'impuissance | |
FR2837101B1 (fr) | Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques | |
FR2810547B1 (fr) | Utilisation d'acides en c2-c10 pour la prevention des infections a bacteries a gram negatif | |
MA25852A1 (fr) | Methode pour le traitement de l'inflammation. | |
EE200200693A (et) | Interferoon hulgiskleroosi raviks | |
FR2811998B1 (fr) | Utilisation d'heteroxylanes pour la preparation de compositions filmogenes | |
MA27530A1 (fr) | Utilisation de la levocetirizine pour le traitement de la rhinite allergique persistante. | |
FI20011560A (fi) | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet | |
FR2825714B1 (fr) | Nouvelle utilisation de complexes d'inclusion de cyclodestrine | |
FR2819823B1 (fr) | Dispositif pour la production de vin rouge |